Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaclotide for IBS-C: Prospective Cohort Study
ChiCTR2300069936Phase 4Completed
- Sponsor
- Chengdu Hospital of Integrated Traditional Chinese and Western Medicine
- Start
- Jun 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of linaclotide in irritable bowel syndrome (IBS) (3 arms), sponsored by Chengdu Hospital of Integrated Traditional Chinese and Western Medicine. Primary endpoint: Complete spontaneous bowel movement. Started Jun 2021; status: completed.
02
Drugs
linaclotide
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on ChiCTR2300069936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069936.